Core Insights - Ipsen announced changes to its Executive Committee, effective September 1, 2025, with Mari Scheiffele, Andreas Gerber, and Caroline Sitbon taking on new roles [1][5][7] Group 1: Executive Appointments - Mari Scheiffele will transition from leading commercial operations in the International Region to overseeing all medicines in Oncology and Rare Disease, focusing on product development and pipeline innovation [2][5] - Andreas Gerber joins Ipsen from Johnson & Johnson as Head of International, responsible for operations outside North America, leveraging his experience in Oncology to drive growth in Ipsen's therapeutic areas [3][5] - Caroline Sitbon has been promoted to General Counsel, leading legal and business ethics, and will also serve as the General Secretary of the Board of Directors [4][5] Group 2: Leadership Perspectives - CEO David Loew expressed confidence in the new appointments, highlighting the combination of internal promotions and new leadership as a strength for Ipsen's ongoing transformation [5] - Mari Scheiffele emphasized her commitment to innovation and excellence in her new role [5] - Andreas Gerber expressed enthusiasm for leading the International Region and making a positive impact on patients' lives [5] - Caroline Sitbon conveyed her excitement about ensuring compliance and integrity within the organization [5] Group 3: Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease, and Neuroscience, with nearly 100 years of development experience [6][8] - The company operates in over 40 countries and provides medicines to patients in more than 80 countries [8]